The "SPARCOL" Study

Colon Cancer Clinical Trial

Official title:

Organ SPARring Surgery vs. Standard Resection for Early Stage COLon Cancer in Elderly Frail Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05734300
• Other study ID #: EMN 2022-04791
• Status: Recruiting
• Phase: N/A
• Start date: May 1, 2023
• Est. completion date: September 1, 2027

Study information

• Verified date: July 2023
• Source: Zealand University Hospital
• Contact: Ilze Ose, MD
• Phone: 27293399
• Email: ilos[@]regionsjaelland.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Mortality following elective colorectal cancer surgery range between 2.5-6% and increase for the elderly and frail patient regardless of T-stage. Around 80% of the patients who present with a colon cancer and is in a condition where surgery is possible will be offered resection of the tumor. A part of the colon is always removed together with the lymph nodes in order to ensure that cancer cells are not left behind. The risk of lymph node metastasis is dependent on several histopathological characteristics of the tumor. The overall risk of lymph node metastases is less than 20 % in patients with early colon cancer. This indicates that the majority of patients with early colon cancer have no benefit of additional resection besides local tumor excision. The alternative to resecting a larger part of the bowel is to make more focused surgery only resecting a small part of the bowel part through a combination of laparoscopic and endoscopic techniques. This new organ sparing approach is called Combined Endoscopic Laparoscopic Surgery (CELS). The investigators aimed to examinate the hypothesis that organ preserving approach (CELS) provides superior quality of recovery in elderly frail patients with small colon cancers when compared with standard surgery in RCT.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: September 1, 2027
• Est. primary completion date: May 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Male and Female participants providing written informed consent aged 75 years and older

• PS score =1 and /or ASA score =3

• Macroscopically or pathological colonic adenocarcinoma

• Clinical TNM classification T1/T2 N0 M0

• Eligible and suitable for CELS resection according to MDT

• Tumor must be located in colon, and not involving the ileac valve or taking up more than 50% of the lumen in an air-distended bowel wall

Exclusion Criteria:

• Unable to give informed consent

• Histological high-risk features in biopsy material from tumor (mucin, signet cells, de- differentiation)

• Suspected other malignancy than adenocarcinoma (e.g. neuroendocrine tumors)

• Preoperative chemo/radiotherapy

• Creation of stoma perioperative

• Non-Danish speakers

Related Conditions & MeSH terms

• Colon Cancer
• Colonic Neoplasms
• Frailty

Intervention

Procedure:
• Combined Endoscopic Laparoscopic Surgery (CELS)
The main surgical advantage in this procedure is the ability to view the colon intra- and extraluminal simultaneously. The laparoscopic approach enables manipulation and mobilization of the colon, while the endoscopic view secures that the resection is complete and not overlapping the ileac valve or creating stenosis. Compared to the traditional oncological colon resection, the CELS resection is a minimally invasive procedure - organ sparing procedure leading to a reduced surgical stress response.
• Standard resection
In this study standard resection of the colon will be performed according to complete mesocolic excision (CME) principles.

Locations

Country	Name	City	State
Denmark	Hospital Soenderjylland	Aabenraa
Denmark	Copenhagen University Hospital - Herlev	Copenhagen	Herlev
Denmark	Zealand University Hospital	Køge

Sponsors (1)

Lead Sponsor	Collaborator
Zealand University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in patient-reported postoperative recovery - Quality of Recovery 15	Validated to measure recovery after surgery and general anesthesia, and additionally validated for use in Danish language and culture. The scale is arbitrary and ranges from 0 to 150. Higher scores means better recovery. The established minimum clinically important difference in QoR-15 is 8.0, and the SD of QoR- 15 scores after major surgery is in the order of 16.	Change in QoR-15 will be assessed repeatedly at baseline, 4-8 hours postoperatively (4-8H), postoperative day (POD) 1, POD 2, POD 3, POD 7, POD 10-14 and POD 30
Secondary	Change in exercise capacity and physical condition	The 30 Second Sit to Stand Test. A measurement that assesses functional lower extremity strength in older adults. Test result is the number of times the participant comes to a full standing position in 30 seconds. Higher number of stands within 30 seconds means better result.	Changes will be assessed repeatedly at baseline, Postoperative day 1, Postoperative day 2, Postoperative day 3 or at the time of hospital discharge, whatever comes first. Postoperative day 10-14 and 30 days postoperatively.
Secondary	Change in exercise capacity and physical condition	Six minutes' walk test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes.	Changes will be assessed repeatedly at baseline, Postoperative day 1, Postoperative day 2, Postoperative day 3 or at the time of hospital discharge, whatever comes first. Postoperative day 10-14 and 30 days postoperatively.
Secondary	Changes in The European Organization for Research and Treatment of Cancer quality of life questionnaire - EORTC C30.	EORTC C30, questionnaire, developed to assess the quality of life of cancer patients. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the patient), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the patient).	Changes will be assessed repeatedly at basline, 3 months, 6 months, 1 year follow-up
Secondary	Changes in The European Organization for Research and Treatment of Cancer quality of life questionnaire- EORTC CRC.	EORTC CRC questionnaire, developed to assess the quality of life of cancer patients. All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the patient), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the patient).	Changes will be assessed repeatedly at basline, 3 months, 6 months, 1 year follow-up
Secondary	Frailty questionnaire Geriatric 8 (G8)	The G-8 Score is a screening tool containing 8 questions. The total G-8 score lies between 0 and 17. A higher score indicates a better health status.	Basline
Secondary	Duration of surgery	Duration of surgery in minutes	Intraoperative
Secondary	Blood loss	Blood loss in ml	Intraoperative
Secondary	Intraoperative complications	Descriptive registration of intraoperative complications;	Intraoperative
Secondary	Conversion rate	Conversion rate (%) from laparoscopic surgery to open surgery	Intraoperative
Secondary	Rate of complete resection margin	R0 (tumor-free margin >1 mm) corresponds to resection for cure or complete remission. R1 to microscopic residual tumor, R2 to macroscopic residual tumor.	Postoperative day 14
Secondary	Assessment of histopathological risk factors	Assessment of histopathological risk factor defined as presence of at least one of the risk factors: Kikuchi level =sm2, vascular invasion, lymphatic invasion, poorly differentiated adenocarcinoma, and tumour budding BD2-3.	Postoperative day 14
Secondary	Long-term oncological outcomes: Disease-free survival	Time from surgery until the recurrence of disease or death	During 3-year follow-up periode
Secondary	Long-term oncological outcomes: Overall survival	Overall survival was defined as the time elapsed from the date of surgery to the last day of follow-up or the date of death	During 3-year follow-up periode
Secondary	Long-term oncological outcomes: Recurrence	Locoregional and/or distant recurrence after surgery defined as any histological, morphological, and clinical evidence of tumour growth during follow-up periode	During 3-year follow-up periode
Secondary	Clavien-Dindo classification	Grading system used in surgery for grading adverse events (i.e. complications) which occur as a result of surgical procedures. Grade I to V, where V is death of the patient	Within 90 days postoperative.
Secondary	The Comprehensive Complication Index	e Comprehensive Complication Index (CCI®) reflects the gravity of this overall complication burden on the patient on a scale from 0 (no complication) to 100 (death)	Within 90 days postoperative.
Secondary	Length of hospital stay	Clinical metric that measures the length of time in days elapsed between a patient's hospital admittance and discharge.	Within 90 days postoperative.
Secondary	90-day mortality	Death within 90 days after surgery, as either an inpatient or outpatient	Within 90 days postoperative.
Secondary	Hospital readmissions	Unplanned readmissions that happen within 3 days of discharge from the index (i.e., initial) admission	Within 90 days postoperative.
Secondary	Rate of secondary standard resection	Rate in percent of performed secondary surgery after primary CELS resection	Within 90 days postoperative.